Cargando…
Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab
BACKGROUND: In a previously reported study, patients with regionally advanced melanoma were treated with neoadjuvant ipilimumab (ipi) (Tarhini in PLoS ONE 9(2): e87705, 3). Significant changes in circulating myeloid derived suppressor cells (MDSC), regulatory T cells (Treg) and peptide specific type...
Autores principales: | Najjar, Yana G., Ding, Fei, Lin, Yan, VanderWeele, Robert, Butterfield, Lisa H., Tarhini, Ahmad A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319167/ https://www.ncbi.nlm.nih.gov/pubmed/28222797 http://dx.doi.org/10.1186/s12967-017-1140-9 |
Ejemplares similares
-
Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab
por: Retseck, Janet, et al.
Publicado: (2016) -
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
por: Tarhini, Ahmad A., et al.
Publicado: (2015) -
Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
por: Tarhini, Ahmad A., et al.
Publicado: (2014) -
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
por: Retseck, Janet, et al.
Publicado: (2018) -
A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab
por: Kobeissi, Iyad, et al.
Publicado: (2023)